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Abstract
Bone development and regeneration is associated with the Wnt signaling pathway that, according to literature, can be
modulated by lithium ions (Li+). The aim of this study was to evaluate the gene expression profile during peri-implant
healing of poly(lactic-co-glycolic acid) (PLGA) implants with incorporated Li+, while PLGA without Li+ was used as control,
and a special attention was then paid to the Wnt signaling pathway. The implants were inserted in rat tibia for 7 or 28 days
and the gene expression profile was investigated using a genome-wide microarray analysis. The results were verified by
qPCR and immunohistochemistry. Histomorphometry was used to evaluate the possible effect of Li+ on bone regeneration.
The microarray analysis revealed a large number of significantly differentially regulated genes over time within the two
implant groups. The Wnt signaling pathway was significantly affected by Li+, with approximately 34% of all Wnt-related
markers regulated over time, compared to 22% for non-Li+ containing (control; Ctrl) implants. Functional cluster analysis
indicated skeletal system morphogenesis, cartilage development and condensation as related to Li+. The downstream Wnt
target gene, FOSL1, and the extracellular protein-encoding gene, ASPN, were significantly upregulated by Li+ compared with
Ctrl. The presence of b-catenin, FOSL1 and ASPN positive cells was confirmed around implants of both groups. Interestingly,
a significantly reduced bone area was observed over time around both implant groups. The presence of periostin and
calcitonin receptor-positive cells was observed at both time points. This study is to the best of the authors’ knowledge the
first report evaluating the effect of a local release of Li+ from PLGA at the fracture site. The present study shows that during
the current time frame and with the present dose of Li+ in PLGA implants, Li+ is not an enhancer of early bone growth,
although it affects the Wnt signaling pathway.
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Introduction
Orthopedic and dental implant therapies have evolved into
important treatments for deranged joints and lost teeth or to
provide fixation of bone in the case of fractures. Osteogenesis, i.e.
the differentiation of mesenchymal stem cells (MSCs) into mature
osteoblasts is essential in bone growth, fracture healing and
osseointegration. The hallmarks of osteogenesis around implants
are increased alkaline phosphatase (ALP) activity and the
formation of a calcium-rich mineralized extracellular matrix
(ECM). This contains bone-related proteins, such as type I
collagen (COL1), osteocalcin (OCN), bone sialoprotein (BSP) and
osteopontin (OPN)[1]. The runt-related transcription factor 2
(RUNX2) is indicated as the master switch in osteogenesis,
although other factors, such as the canonical Wnt signaling
pathway are pivotal for the guidance of MSCs into the osteoblastic
lineage and bone homeostasis[2,3]. The canonical Wnt signaling
pathway involves several Wnt proteins that, upon activation, bind
to receptors frizzled (FZD) and co-receptor LDL-related proteins
5/6 (LRP5/6). This interaction initiates a signaling cascade that
leads to the inactivation of the b-catenin (CTNNB1) degradation
complex, consisting of AXIN, adenomatous polyposis coli (APC),
casein kinase I (CK1) and glycogen synthase kinase 3b (GSK-3b).
The intracellular b-catenin concentrations then become stabilized,
translocated into the nucleus and activate the transcription of
downstream canonical Wnt-related genes. The non-canonical
pathways, which function independently of b-catenin, are less well
studied but attract increasing interest. Recent studies suggests the
FZD9 receptor as a positive regulator of both intramembranous
and endochondral ossification during fracture healing via the non-
canonical pathways[4,5], although the canonical Wnt signaling
pathway is implicated as the dominant mechanism in bone
biology. The critical role of Wnt signaling is well recognized, not
only during embryonic bone formation, post-natal bone homeo-
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stasis and regeneration but also for osseointegration of implants[6–
8]. Of several ways to modulate the Wnt signaling pathway,
lithium ions (Li+) are often regarded as the simplest activa-
tor[9,10]. Oral Li+ treatment, widely used as stabilizer in bipolar
and depressive disorders, is reported to activate the canonical Wnt
signaling pathway via the inhibition of the b-catenin degradation
enzyme, GSK-3b[11,12]. Previous studies indicated that Li+
induces increased bone formation and bone mass in mice, as well
as reduce the risk of fractures in patients on Li+ treatment[13,14].
However, due to the fact that Li+ has a narrow therapeutic index
and the therapy is associated with multiple side-effects[11], it
would be beneficial in biomaterial applications to enhance bone
regeneration via a local release of Li+ from bioactive degradable
materials. The objective of the present study was to incorporate
Li+ into poly(lactic-co-glycolic acid) (PLGA) implants, to monitor
the local release of Li+ and to evaluate the local biological effects
by gene expression, immunohistochemistry, histology and histo-
morphometry in a rat tibia model. PLGA is a biodegradable co-
polymer that is widely used in pharmaceutics as a controlled drug
delivery system[15] and it has evolved into a frequently used
synthetic polymer within the field of bone regeneration[16]. One
reason for its widespread use is its biodegradability and
biocompatibility. In the presence of water, PLGA degrades via
hydrolysis into lactic and glycolic acids, natural compounds that
are metabolized and excreted as carbon dioxide and water[16,17].
PLGA is in clinical use since decades and its biosafety is proven in
many medical applications[16,18]. It has been used as a carrier for
the delivery of osteogenic factors for cell adhesion, differentiation
and improved bone regeneration, as pure PLGA implants or in
combination with hydroxyapatite (HA) to obtain an improved
mechanical strength[19–23]. To study the effect of Li+, the ions
have previously been incorporated into various materials or added
directly to cell culture media[24–27]. However, there is no
previous study using Li+-PLGA implants with the aim to modulate
the Wnt signaling pathway in vivo. In order to fully investigate the
underlying cellular and molecular mechanisms of peri-implant
healing within this context, we performed a genome-wide
microarray analysis, followed by validation of selected results by
qPCR, in combination with a histomorphometric evaluation.
Previous works used gene expression profiling during in vivo bone
healing, with or without implants[28–32], but this is to the best of
the authors’ knowledge, the first in vivo study to evaluate the bone
healing aspects in the vicinity of Li+-containing PLGA implants.
We were able to show that the present dose of Li+ activates the
Wnt signaling pathway but is not an inducer of early bone growth.
In addition to providing insights into Wnt signaling during peri-
implant healing around bone-anchored implants, this study shows
that a local release of Li+ at the fracture site can be used to
modulate bone cell signaling but needs further optimization in
order to induce early bone growth.
Materials and Methods
Li+-PLGA implant fabrication, characterization and Li+
release profile
Lithium salt containing plug-shaped samples and control
samples made of sodium salt were prepared as follows. 10 g of
lithium carbonate (Sigma Aldrich, St. Louis, MO, USA) or sodium
carbonate salts (Sigma Aldrich) were ground manually with a
mortar and pestle. The ground powder was transferred to and
sieved through a set of sieves with sizes 45–180 mm at maximum
amplitude for 5 minutes using a vibratory sieve shaker (Rietsch,
Germany). A batch of 10 g lithium carbonate or sodium carbonate
salt generated a 45–90 mm sieve fraction of about 2 g salt. The
ground and sieved salts were mixed with 50:50 PLGA powder,
MW 24,000–38,000 (Sigma Aldrich) at a 1:10 ratio (w/w), hot-
melt pressed at 100uC and pre-pelletized. The PLGA pellets with
included salt were repeatedly fed into a HAAKE MiniLab
rheometer (Thermo Scientific, Rockford, IL, USA), at 100uC,
speed 60 l/min, and extruded through a die with a diameter of
1.6 mm. The strains were cut and heat-molded to form a plug
with dimensions: dhead = 3.5 mm, dshank = 1.8–2.0 mm,
ltot = 3.2 mm, h = 1.0 mm. The weight of a plug was typically
17 mg. The salt containing PLGA sample plugs will henceforth be
designated Li+ and Ctrl implant, respectively.
Scanning Electron Microscopy
The internal pore structure, morphology and porosity of the
cross-sectioned implants were characterized by a field emission
scanning electron microscope (SEM, Leo Ultra 55 FEG SEM, Leo
Electron Microscopy Ltd, Cambridge, UK) at 3 kV. The implants
that had undergone ion release experiments (day 0–28; see below)
were embedded in plastic resin (LR White; Sigma-Aldrich) and
polymerized prior to cutting along the long axis of the implant,
sputter-coated with gold before analysis and visualized using the
in-lens detection mode.
TOF-SIMS Imaging
The chemical characterization of the implants was performed
with time-of-flight secondary ion mass spectrometry (TOF-SIMS,
TOF-SIMS IV, ION-TOF GmbH, Mu¨nster, Germany), using a
primary ion beam of 25 keV Bi3+ ions. The specimens were
embedded in plastic resin (as described above). A thin section was
prepared by cutting and grinding to achieve a final thickness of
10–20 mm and the samples were cleaned in N2 gas before analysis.
In order to evaluate the Li+ distribution in the implant during in
vitro degradation, stage scan imaging of positive ions was
performed in the bunched mode (PI target current 0.1 pA).
Li+ release in vitro
For Li+ release profile analysis, PLGA implants with included
lithium carbonate salt were submerged in 10 mL PBS buffer,
pH 7.2, and agitated at 37uC for 4 weeks on a rotating table.
Samples of 1 mL were collected at specified time points and
replaced by 1 mL PBS buffer. Li+ levels were well below sink
conditions throughout the experiment. The amount of released Li+
was determined using flame emission spectrometry (iCE 3300 AA
Spectrometer, ThermoScientific, Germany), with a detection
wavelength of 670.8 nm.
Ethics Statement
The research described in this study involving animal experi-
ments was approved by the University of Gothenburg’s Local
Ethical Committee for Laboratory Animals (Dnr: 279–2011).
Surgical procedure
The implants were sterilized by ultra violet (UV) treatment for
1 hour and endotoxin analysis was performed with Limulus
amebocyte lysate using a kinetic chromogenic method (Charles
River, L9arbresle Cedex, France), and run according to the FDA
protocol. All implants showed values below the recommended
maximum level of 1.25 endotoxin units (EU) per rat (250 g)
(Sahlgrenska Hospital, Gothenburg, Sweden). Thirty-four male
Sprague-Dawley rats (390–400 g), fed on a standard pellet diet
and water, were anesthetized using a Univentor 400 anesthesia
unit (Univentor, Zejtun, Malta) under isoflurane (Isoba Vet,
Schering-Plough Uxbridge, England) inhalation (4% with an air
Activated Wnt Signaling Pathway around Li+-PLGA Implants
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flow of 650 mL/min). Anesthesia was maintained by the
continuous administration of isoflurane (2.7% with an air flow of
450 mL/min) via a mask, and all efforts were made to minimize
suffering. Each rat received analgesic (Temgesic 0.03 mg/kg,
Reckitt & Coleman, Hull, Great Britain) subcutaneously prior to
implantation and every day postoperatively. After shaving and
cleaning (5 mg/mL chlorhexidine in 70% ethanol), the medial
aspect of the proximal tibial metaphysis was exposed through an
anteromedial skin incision, followed by skin and periosteum
reflection with a blunt instrument. After bone preparation with
1.8- and 2.1-mm burrs under profuse irrigation with NaCl 0.9%, 2
implants (one from each implant group) were inserted manually in
each rat tibia. The locations of implants were decided using a
predetermined schedule, ensuring alteration between the legs and
sites. The subcutaneous layer of the wound was closed with
resorbable polyglactin sutures (5-0, Vicryl, Ethicon, Johnson &
Johnson, Brussels, Belgium) and the skin was closed with
transcutaneously placed non-resorbable nylon sutures (4-0,
Ethilon, Ethicon, Johnson & Johnson). The animals were allowed
free postoperative movement, with food and water ad libitum. The
retrieval procedure was performed at 7 and 28 days (17 rats at
each time point). The rats were sacrificed using an intraperitoneal
overdose of sodium pentobarbital (60 mg/mL; ATL Apoteket
Production & Laboratories, Sweden) under anesthesia, with a
0.5 mL mixture of pentobarbital (60 mg/mL), sodium chloride
and diazepam (1:1:2) and cleaned with 5 mg/mL of chlorhexidine
in 70% ethanol. After cutting the sutures, an incision of the skin
and a reflection of the periosteum were performed. For transcript
profiling analyses, peri-implant bone was carefully collected using
a 3.8 mm diameter trephine burr and immediately placed in RNA
preservation solution and stored at 4uC until analysis. In addition,
bone-implant blocks were fixated for subsequent microscopic
examination.
RNA isolation
Bone samples were homogenized in a phenol/guanidine-based
Qiazol lysis reagent, using 5-mm stainless steel beads (QIAGEN
GmbH, Hilden, Germany) and TissueLyser (QIAGEN). Following
the addition of chloroform, the samples were centrifuged at
12,000 g for 15 min and the aqueous phase was used for
subsequent RNA extraction. Total RNA from the surrounding
bone was extracted using a RNeasy Mini kit (QIAGEN),
according to the manufacturer’s instructions. DNAse treatment
was performed in order to eliminate any contamination from
genomic DNA. The quantification and quality assessment of RNA
was performed using the Agilent Bioanalyzer (Agilent Technolo-
gies, Santa Clara, CA, USA) and NanoDrop spectrophotometer
(Thermo Scientific, Rockford, IL, USA). All samples were of
similar RNA quality and integrity (RIN.8).
Global transcriptional and microarray data analysis
Total RNA (200 ng) from 12 peri-implant bone samples/time
point (n = 6 Li+; 6 = Ctrl) was subjected to gene expression analysis
using the Affymetrix Rat Gene 2.0 ST Array (Affymetrix, Santa
Clara, CA, USA), and handled according to the manufacturer’s
recommendations. Expression data were normalized and summa-
rized using the RMA algorithm implemented in the Affymetrix
Expression Console version 1.1.2 software[33]. T-test analyses
(paired; Li+ vs. Ctrl and unpaired; Li+ day 28 vs. 7, Ctrl day 28 vs.
7) were performed on log2-transformed signal values to identify
significantly differentially expressed genes between groups, using
the TMEV v4.0 software. Expression differences were given as
fold changes (FCs); only significantly altered genes that displayed a
mean fold change of FC$1.5 or#21.5 (p,0.05) were selected for
further analysis. To further investigate the biology of the
differentially regulated genes, the DAVID software tool[34,35]
(http://david.abcc.ncifcrf.gov/) was used to explore their gene
ontology (GO) annotations according to biological processes. To
identify significantly differentially regulated pathways and specific
Wnt signaling-related genes during the peri-implant healing
processes, the KEGG pathway database (http://www.genome.
jp/kegg/) was used. All significantly regulated genes (p,0.05)
obtained from the microarray analysis (no specific FC limit) were
included in the gene list. The microarray data discussed in this
publication followed MIAME requirements and have been
deposited in NCBI’s Gene Expression Omnibus (GEO)[36] with
the GEO Series accession number GSE54294.
Quantitative real-time PCR (qPCR) analysis
Briefly, RNA was transcribed to cDNA using a HighCapacity
cDNA Reverse Transcription Kit (Life Technologies, Carlsbad,
USA), according to the manufacturer’s instructions. The
instrument, 7900 HT, software and reagents for the real-time
qPCR analysis were purchased from Life Technologies. The
commercially available assay-on-demand mixes of primers and
TaqMan MGB probes (FAM dye-labeled) were used in this
study: ACAN (Rn00573424_m1), ASPN (Rn01757407_m1),
A2M (Rn00560589_m1), CXCL2 (Rn00586403_m1), DKK1
(Rn01501537_m1), FOSL1 (Rn00564119_m1), FZD2
(Rn00597004_s1), LRP5 (Rn01451428_m1), PRKCA
(Rn01496145_m1), PRSS34 (Rn01466862_g1) and SFRP5
(Rn01766277_m1). 18s (Hs9999901_s1) was used as an endog-
enous control. cDNA corresponding to 2.5 ng total RNA were
analyzed in duplicate for all samples (n = 8). Relative gene
expression level (the amount of target, normalized to the
endogenous control gene) was calculated using the 22DDCt
method[37] in GenEx Enterprise 5.2.3.13 (MultiD analyses,
Gothenburg, Sweden) and expressed as relative quantities
normalized to the Ctrl group at 7 days post-surgery, with a
given reference value 1.
Histology and Immunohistochemistry
For histological evaluations, the bone-implant specimens were
harvested, PLGA remnants were removed from the defect site and
the tissue blocs were fixated in formalin, dehydrated and
embedded in paraffin and sectioned (3–5 mm). The sections were
subsequently mounted on StarFrost slides (Waldemar Knittel
Glasbearbeitungs-GMbH, Braunschweig, Germay) and main-
tained at 60uC in an oven for 1 h. The sections were either
stained with hematoxylin/eosin (HE; Merck KGaA, Darmstadt,
Germany) for histological evaluation or processed for immuno-
histochemical (IHC) staining; the sections were deparaffinized in
xylene, hydrated in descending series of ethanol and treated with
3% H2O2, and antigen retrieval with 10 mM citrate buffer was
performed. Slides were blocked with 3% BSA for non-specific
antibody binding before incubation with either of primary
antibodies from Abcam (Abcam, Cambridge, MA, USA); b-
catenin (ab16051), FOSL1 (ab117951), ASPN (ab58741), periostin
(ab14041) and calcitonin receptor (ab11042). As negative controls,
some tissue samples were incubated without the primary antibody
or with isotype controls (data not shown). The primary antibody
was visualized using HRP-conjugated secondary antibodies and a
Betazoid DAB (3,30-diaminobenzidine) Chromogen kit (Biocare
Medical, Concod, CA, USA). All slides were counterstained with
Mayer’s hematoxylin (Merck KGaA) and examined with light
microscopy (Nikon Eclipse E600).
Activated Wnt Signaling Pathway around Li+-PLGA Implants
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Histomorphometry
HE-stained sections were used for a blinded quantitative
histomorphometric analysis by measuring the bone area (BA)
around the implantation site. The BA was measured in the square
area extending 500 mm from the implantation/defect site into
bone. In order to capture all areas dominated by newly formed
bone, the analysis was performed on two separate compartments –
Part A (longitudinally with the plug) and Part B (underneath the
plug). The analysis was performed at 106magnification and all
specimens were evaluated using light microscopy (Nikon Eclipse
E600, Japan).
Statistics
The statistical analysis was performed with GenEx (MultiD
analyses) and SPSS v19 (IBM Corp., Armonk, NY, USA) software.
Logarithmic values of the gene-expression data were used for
statistical calculations. Statistical significance was determined using
Student’s t-test (paired; Li+ vs. Ctrl and unpaired; Li+ day 28 vs. 7,
Ctrl day 28 vs. 7). When the normal distribution of the data could
not be guaranteed, equivalent non-parametric tests were used. A
significant difference was assumed at a p-value of #0.05. Unless
otherwise stated, the data are expressed as the mean 6 standard
deviations.
Results
In vitro characterization of PLGA implants
The aim with incorporation of Li+ into PLGA implants was to
obtain a locally controlled release of Li+ out to the surrounding
bone. The in vitro implant characterization was performed in
order to follow eventual changes in implant morphology upon the
Li+ release to buffer. The implant surfaces displayed initially a
smooth surface with few irregularities and limited presence of
visible pores (Fig. 1A). A dense morphology with some irregular-
ities, small pores and cavities were observed at the surface of cross-
sectioned, non-submerged Li+- and Na+-containing (Ctrl) implants
(day 0) (Fig. 1B and E, respectively). Larger pores were observed at
the bottom part of the Ctrl implant (Fig. 1E), although these were
judged as artifacts created during sample preparation. The cross-
sections of Li+-containing samples submerged for 7 or 28 days in
buffer showed large cavities at the outer part of the shaft (Fig. 1C
and D, respectively). A similar morphology was observed for the
Ctrl samples, although with less porosity after 7 days compared to
Li+ specimens (Fig. 1F and G, respectively). The cavities on Li+-
containing implants after 7 days of immersion in PBS were mainly
located at the outer part of the shaft, but after 28 days both types
of implants showed cavities also in the central part. Due to artifacts
created during sample preparation for microscopy analysis, only
fragments of Ctrl implant submerged for 28 days could be
visualized by SEM, see Figure 1G. The sizes of the cavities
increased over time for both implant types. The TOF-SIMS
analysis showed the Li+ content in Li+-containing implants
(Fig. 2A) compared to Ctrl implants (Fig. 2B) at day 0. Pores
and air bubbles appeared as black circles in the image. Air bubbles
were trapped during sample preparation and were mainly found
between the implant and the embedding material. The results
confirmed the appearance in SEM images, demonstrating
increasing porosity with time, starting from the outside and
protruding inwards in the shaft region. The total ion content
intensity decreased slightly over time, but remained over the
complete polymer matrix part of the implant. The Li+ ion intensity
was, however, most intense at the inner part of the implant shaft
(data not shown). Figure 3 shows Li+ release from PLGA implants
during 0–28 days in PBS buffer, demonstrating a sustained, almost
linear release of Li+, reaching about 50% of total Li+ content at 28
days. (The results further show a tendency towards a slightly lower
release rate after 22 days.)
Figure 1. Scanning electron micrographs of PLGA implant
cross-sections. SEM images showing surface and cross-sections of
PLGA implants exposed to PBS buffer for 0, 7 and 28 days. A. Surface of
Li+- or Na+-containing (Ctrl) implants, day 0 and B. cross-section of Li+-
containing and E. Ctrl implant not exposed to buffer, day 0. C. Cross-
sections of Li+-containing and F. Ctrl implant after submersion (day 7)
or D. Li+-containing and G. Ctrl implant day 28 in PBS buffer. Design
and surface of plug-shaped PLGA implant, see insert A. Implant
dimensions; dhead = 3.5 mm, dshank = 1.8–2.0 mm, ltot = 3.2 mm,
h = 1.0 mm. Pores and air bubbles created during sample preparation
for microscopy analysis appeared as black circles in images and were
mainly found between the implant and embedding material. The
hatched line defines the shape of the plug.
doi:10.1371/journal.pone.0102597.g001
Figure 2. TOF-SIMS ion imaging stage scans of PLGA implants.
Images show the Li+ intensity (the sum of intensities for the isotopes 6Li
and 7Li) of A. Li+-containing PLGA implant and B. Ctrl implant without
Li+, at day 0.
doi:10.1371/journal.pone.0102597.g002
Activated Wnt Signaling Pathway around Li+-PLGA Implants
PLOS ONE | www.plosone.org 4 July 2014 | Volume 9 | Issue 7 | e102597
Microarray analysis
In order to explore the regulatory mechanisms by which the
incorporated Li+ affected the peri-implant healing, a genome-wide
microarray analysis of the peri-implant bone was performed at 7
and 28 days postoperatively, see Table 1. A total of 1,042 genes
were differentially expressed at day 7 of Li+ implant vs. Ctrl and
1,348 genes at the later time point (Tables S1–S2). The over-time
analysis of each implant group showed 3,359 genes differentially
regulated in the control group (Ctrl day 28 vs. 7), and 4,752 genes
in the Li+ group (Li+ day 28 vs. 7) (Tables S3–S4). In-depth search
for genes fulfilling the search criteria (FC$1.5 or #21.5) revealed
only a few genes (3–5) as differentially regulated by Li+ compared
with Ctrl (Tables S1–S2). Over-time analyses revealed 311
differentially regulated genes in the control group; 69 upregulated
and 242 downregulated (Table S3). The Li+ group showed 342
regulated genes; 111 upregulated and 231 downregulated (Table
S4).
Functional cluster analysis
A functional cluster analysis based on the GO category
biological processes was carried out on genes that fulfilled the
search criteria. For the Li+-containing specimens, the analysis
showed 29 downregulated clusters over time; 10 clusters with the
highest enrichment scores are listed in Table S5. These were
related to extracellular matrix organization, inflammatory re-
sponse, cell migration, blood vessel development and skeletal
system, and cartilage development and condensation. For the Li+
group, 2 annotation clusters were upregulated over time; wound
healing and regulation of cell activation (Table S6). For the Ctrl
group, 25 annotation clusters were downregulated over time; 10
clusters with the highest enrichment scores are listed in Supporting
information Table S7. The clusters were related to extracellular
matrix organization, inflammatory response, cell migration, blood
vessel development and skeletal system, bone development and
ossification. Only 1 annotation cluster related to the regulation of
cell activation was upregulated (Table S8).
Clustering of inflammation associated genes
The above mentioned functional cluster analysis demonstrated
a slight change in enrichment score between Li+ and Ctrl implants
with respect to inflammation. The Li+ group revealed clusters
related to the terms ‘‘Inflammatory response’’ and ‘‘Defense
response’’ with an enrichment score of 2.83 (cluster #6, Table S5).
The Ctrl group also demonstrated clusters associated to these
specific clusters, but additionally also related to the term ‘‘Acute
inflammatory response’’ (see cluster #3, Table S7), and showed a
higher enrichment score; 3.67. Some of the most differentially
expressed genes within these clusters were A2M (FC - 4.01 Li+; FC
- 3.19 Ctrl), CCL7 (FC - 3.64 Li+; FC - 2.72 Ctrl), and CXCL2 (FC
- 4.76 Ctrl), see Tables 2 and 3.
Pathway analysis and differentially expressed Wnt-
related markers
In order to explore the pathways that could be differentially
expressed over time in both implant groups, the KEGG pathway
database was searched with the genes differentially expressed as
input. For the Li+ specimens, 9 pathways were downregulated at
day 28 compared with 7 days post-surgery (Table 4). The KEGG
term ‘‘Pathways in cancer’’ (Rno:05200) was one of them; this
term includes the Wnt signaling pathway (Rno:04310). Only 2
pathways were shown to be upregulated on day 28 compared with
day 7 in the Li+ group, see Table 5. For the Ctrl group 6 pathways
with decreased expression 28 days post-surgery were revealed
(Table 6). No pathways were significantly upregulated over time.
The presence of the Wnt signaling pathway in the Li+ group but
not in the Ctrl demonstrates that the Wnt signaling network was
regulated over time in the presence of Li+. Since this recognized
Wnt activator was used in this study, a more specific search was
Figure 3. In vitro Li+ release profile in PBS. Percentage (%) release
of Li2CO3 from PLGA implants (error bars represent the standard
deviations, n = 3).
doi:10.1371/journal.pone.0102597.g003
Table 1. Differentially regulated genes.
Numbers of differentially regulated genes (p,0.05, no specific FC limit)
Total Increase Decrease
Li+ day 7 vs. Ctrl 1042 427 615
Li+ day 28 vs. Ctrl 1348 684 664
Ctrl day 28 vs. 7 3359 1465 1894
Li+ day 28 vs. 7 4752 2439 2313
Numbers of differentially regulated genes (p,0.05, FC$1.5 or #21.5)
Total Increase Decrease
Li+ day 7 vs. Ctrl 3 1 2
Li+ day 28 vs. Ctrl 5 1 4
Ctrl day 28 vs. 7 311 69 242
Li+ day 28 vs. 7 342 111 231
For complete lists, refer to Tables S1–S4.
doi:10.1371/journal.pone.0102597.t001
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performed on all Wnt-related significantly regulated genes,
according to the KEGG database. Four genes were differentially
expressed on day 7 in Li+ implants vs. Ctrl and, at the later time
point, 9 genes. The analysis revealed 34 Wnt-related genes
differentially regulated over time within the Li+ group and 22
genes in the Ctrl group (Table 7 and Tables S9–12). Interestingly,
the negative Wnt regulator, b-catenin interaction protein 1
(CTNNBIP1), was downregulated at 7 days after implantation
in the Li+ group (FC -1.12) (Table S9). Moreover, b-catenin
(CTNNB1) was downregulated at 28 days post-surgery in the
presence of Li+ (FC -1.21), but was not affected in the Ctrl group
(Tables S11–12).
qPCR validation of microarray data
In order to confirm the gene expression profile from the
microarray analysis, the expression of some of the most
differentially regulated genes over time from both groups was
further analyzed by qPCR (Table 8). The overall FC obtained
from the microarray tended to be smaller than that from the
qPCR analysis, although the datasets were largely in accordance
with each other, verifying the microarray results. In the gene array
dataset (Tables S9–10), we observed no major differences between
the Li+ and Ctrl groups. However, qPCR revealed a difference in
gene expression between Li+ and Ctrl for the Wnt related genes
FOSL1 and ASPN. At 7 days post-surgery, the mRNA
corresponding to the FOSL1 gene showed a significant FC
increase of about 1.7 for the Li+ group as compared with Ctrl
(p = 0.012, Fig. 4A), whereas the ASPN gene displayed a
significantly increased FC of around 3.5 at 28 days for the Li+
group compared to Ctrl (p = 0.03, Fig. 4B).
Verification of b-catenin, FOSL1 and ASPN expression
In order to verify the microarray data, the spatial protein
expression of b-catenin, FOSL1 and ASPN was studied in peri-
implant bone retrieved from Li+-containing and Ctrl implants.
The proteins were investigated due to their involvement in Wnt
signaling and/or increased gene expression by microarray and
qPCR. The expression of b-catenin, FOSL1 and ASPN was
verified at both time points in bone from both the Li+ and Ctrl
samples, although no qualitative or quantitative histological
differences were observed between the implant groups. Positive
immunoreactivity for these proteins was demonstrated in perios-
teum and bone marrow cavities, as well as on cells situated in the
close vicinity of the bone-implant interface (Fig. 5A-I).
Histomorphometry, histology and
immunohistochemistry
Histomorphometry of HE-stained sections revealed no signifi-
cant differences in bone area (BA) between Li+ and Ctrl groups at
any time point (Fig. 6A, exam areas see Fig. 6B). On the other
hand, a significant decrease in BA over time was demonstrated for
both groups; Li+ 7 days 35.58%64.20% vs. 28 days;
23.53%64.29% (p = 0.0003) and Ctrl 7 days 32.51%66.15%
vs. 28 days 21.89%66.52% (p = 0.008) (Fig. 6A). The spatial
locations of periostin and calcitonin receptors were studied in
decalcified paraffin-embedded sections of the tissue defect, 7 and
28 days postoperatively. Periostin-positive cells were distributed
throughout the regenerated tissue and osteoblast bone-lining cells
were strongly stained for periostin. Positive staining for the
calcitonin receptor was observed at 7 days, on both mono- and
multinucleated cells localized at osteoblast seams on the bony
surfaces facing the bone marrow and at the bone-implant
interface. Similar patterns were detected 28 days postoperatively.
No qualitative or quantitative histological differences were
observed between the implant groups (Fig. 7A-F).
Discussion
The inclusion of Li+ in PLGA was obtained by a hot-melt
procedure, resulting in the incorporation of 10% (w/w) Li2CO3/
implant. The SEM and TOF-SIMS imaging data demonstrated
how the polymer implant transformed in appearance from a dense
Table 2. Inflammation associated genes downregulated in Li+ day 28 vs. 7.
Probe Set ID Gene Accession Gene Symbol Gene Description
FC Li+ day
28 vs 7 P-value
17786724 NM_012488 A2M Alpha-2-macroglobulin 24.01 3.10E-05
17649432 NM_001007612 CCL7 Chemokine (C-C motif) ligand 7 23.64 5.32E-04
17649426 NM_031530 CCL2 Chemokine (C-C motif) ligand 2 22.60 9.23E-04
17711968 ENSRNOT00000014809 SLC7A2 Solute carrier family 7 (cationic amino acid
transporter, y+ system), member 2
22.15 2.76E-04
17812245 ENSRNOT00000020316 PDPN Podoplanin 21.95 0.002
17659402 NM_013025 CCL3 Chemokine (C-C motif) ligand 3 21.81 0.025
17680795 ENSRNOT00000003567 PTGS2 Prostaglandin-endoperoxide synthase 2 21.79 0.043
17742303 NM_013057 F3 Coagulation factor III (thromboplastin,
tissue factor)
21.79 0.006
17777192 NM_031512 IL1B Interleukin 1 beta 21.72 0.045
17667363 ENSRNOT00000040065 EPHA3 Eph receptor A3 21.72 0.005
17718447 XM_225216 S1PR3 Sphingosine-1-phosphate receptor 3 21.67 0.005
17637979 NM_053420 BNIP3 BCL2/adenovirus E1B interacting protein 3 21.62 0.017
17759790 NM_022194 IL1RN Interleukin 1 receptor antagonist 21.60 0.002
17795409 NM_133306 OLR1 Oxidized low density lipoprotein (lectin-like)
receptor 1
21.56 0.015
Data derived from the annotation cluster #6 in Table S5.
doi:10.1371/journal.pone.0102597.t002
Activated Wnt Signaling Pathway around Li+-PLGA Implants
PLOS ONE | www.plosone.org 6 July 2014 | Volume 9 | Issue 7 | e102597
Table 3. Inflammation associated genes downregulated in Ctrl day 28 vs. 7.
Probe Set ID Gene Accession Gene Symbol Gene Description
FC Ctrl day
28 vs 7 P-value
17693459 ENSRNOT00000003745 CXCL2 Chemokine (C-X-C motif) ligand 2 24.76 0.047
17786724 NM_012488 A2M Alpha-2-macroglobulin 23.19 2.15E-04
17649432 NM_001007612 CCL7 Chemokine (C-C motif) ligand 7 22.72 0.002
17676856 ENSRNOT00000001916 SERPINE1 Serpin peptidase inhibitor, clade E (nexin,
plasminogen activator inhibitor type 1),
member 1
22.54 7.63E-04
17649426 NM_031530 CCL2 Chemokine (C-C motif) ligand 2 22.38 0.002
17659402 NM_013025 CCL3 Chemokine (C-C motif) ligand 3 22.35 1.22E-04
17726248 NM_017061 LOX Lysyl oxidase 22.18 0.018
17610985 NM_017134 ARG1 Arginase, liver 22.17 0.002
17711968 ENSRNOT00000014809 SLC7A2 Solute carrier family 7 (cationic amino acid
transporter, y+ system), member 2
22.13 0.005
17812245 ENSRNOT00000020316 PDPN Podoplanin 22.08 0.020
17667363 ENSRNOT00000040065 EPHA3 Eph receptor A3 21.98 0.011
17687457 ENSRNOT00000003313 TGFB2 Transforming growth factor, beta 2 21.98 0.009
17747609 ENSRNOT00000018628 IGSF10 Immunoglobulin superfamily, member 10 21.96 0.026
17759790 NM_022194 IL1RN Interleukin 1 receptor antagonist 21.85 0.001
17672282 NM_012801 PDGFA Platelet-derived growth factor alpha
polypeptide
21.84 0.008
17795409 NM_133306 OLR1 Oxidized low density lipoprotein (lectin-like)
receptor 1
21.79 0.024
17630332 ENSRNOT00000041891 APOE Apolipoprotein E 21.72 0.007
17625032 NM_001106375 PAPSS2 39-phosphoadenosine 59-phosphosulfate
synthase 2
21.72 0.022
17725368 ENSRNOT00000027739 NREP Neuronal regeneration related protein 21.69 0.023
17858944 NM_032085 COL3A1 Collagen, type III, alpha 1 21.67 0.030
17746926 ENSRNOT00000019554 ANXA5 Annexin A5 21.62 0.002
17731914 NM_031054 MMP2 Matrix metallopeptidase 2 21.58 0.033
17742303 NM_013057 F3 Coagulation factor III (thromboplastin, tissue
factor)
21.57 0.003
17734841 NM_017091 PCSK1 Proprotein convertase subtilisin/kexin type 1 21.56 0.007
17718447 XM_225216 S1PR3 Sphingosine-1-phosphate receptor 3 21.54 0.018
17719775 NM_080405 GLI3 GLI family zinc finger 3 21.54 0.041
17789522 ENSRNOT00000013989 TFPI2 Tissue factor pathway inhibitor 2 21.52 0.041
Data derived from the annotation cluster #3 in Table S7.
doi:10.1371/journal.pone.0102597.t003
Table 4. KEGG pathways with genes downregulated in Li+ day 28 vs. 7.
KEGG ID Term Count P-value
rno04360 Axon guidance 9 1.49E-04
rno04510 Focal adhesion 10 5.88E-04
rno04512 ECM-receptor interaction 6 0.003
rno00330 Arginine and proline metabolism 5 0.004
rno05211 Renal cell carcinoma 5 0.010
rno05200 Pathways in cancer 10 0.015
rno05210 Colorectal cancer 5 0.017
rno04060 Cytokine-cytokine receptor interaction 7 0.034
rno04621 NOD-like receptor signaling pathway 4 0.041
Count indicates the total number of genes from the input list that belong to the corresponding term; only significantly expressed genes (no specific FC limit) were
included in the gene list.
doi:10.1371/journal.pone.0102597.t004
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to a porous morphology with time. The increased porosity was
initiated at the surface of the shaft and spread towards the center.
The recognized degradation mechanisms of biodegradable poly-
mers are surface or bulk erosions. Bulk erosion is the dominant
mechanism, as water penetrates into the matrix and the
degradation occurs in the inner parts of the matrix, leading to
an equally distributed porosity. For matrices with dimensions
below 7 cm, like our implants, the suggested degradation
mechanism is bulk erosion[38]. However, our experimental
findings, showing increased porosity close to the surface, indicate
that surface erosion contributed largely to the erosion of the
device. Furthermore, the in vitro Li+ release rate was almost
constant over time, indicating that the release mechanism follows
Case II, i.e. water penetration was the rate-limiting factor and not
the drug diffusion out from the device. Inside the PLGA matrix,
the highly water-soluble Li2CO3 was distributed in the shape of
particles. When the water front reached the Li2CO3 particles,
these dissolved rapidly and Li+ diffused out from the matrix, after
which the location of the former Li2CO3 particles turned into
water-filled pores. The rate-limiting step for Li+ release was
therefore the water penetration rate. Simultaneously, the pore
formation observed in SEM and TOF-SIMS was also controlled
by water penetration. After 28 days of exposure to buffer, about
50% of the Li+-salt content was released, and even though highly
perforated the implants still held together. In order to obtain a
complete PLGA degradation or a larger amount of released salt,
the formulation has to be further optimized. The mode of
degradation in bone is also expected to be different from that of a
fully submerged implant in PBS buffer, because of the uniqueness
of the bone environment. However, assuming an equal in vitro
and in vivo release rate, this means that during 28 days, about 2.3
1025 mol Li+ was released to the bone environment around the
implants.
The results of the microarray analysis revealed the largest
number of significantly differentially regulated genes within each
respective implant group over time and the Li+-containing
implants induced a somewhat higher total number of regulated
genes compared with Ctrl. This is in line with a recent study by
Thalji et al.[28] and illustrate the complex process of intramem-
branous bone regeneration; the principal healing route around
bone-anchored implants[29]. In a process like this, including an
initial inflammatory phase followed by osteogenesis, woven bone
formation and finally bone remodeling, it is likely that minor
alterations induced by the different implants become hidden in the
Table 5. KEGG pathways with genes upregulated in Li+ day 28 vs. 7.
KEGG ID Term Count P-value
rno04640 Hematopoietic cell lineage 6 1.99E-05
rno04512 ECM-receptor interaction 5 4.11E-04
Count indicates the total number of genes from the input list that belong to the corresponding term; only significantly expressed genes (no specific FC limit) were
included in the gene list.
doi:10.1371/journal.pone.0102597.t005
Table 6. KEGG pathways with genes downregulated in Ctrl day 28 vs. 7.
KEGG ID Term Count P-value
rno04510 Focal adhesion 12 4.87E-05
rno04512 ECM-receptor interaction 8 9.27E-05
rno00330 Arginine and proline metabolism 6 6.60E-04
rno04360 Axon guidance 7 0.006
rno04062 Chemokine signaling pathway 7 0.026
rno04621 NOD-like receptor signaling pathway 4 0.049
Count indicates the total number of genes from the input list that belong to the corresponding term; only significantly expressed genes (no specific FC limit) were
included in the gene list.
doi:10.1371/journal.pone.0102597.t006
Table 7. Number of differentially regulated Wnt genes.
Total Increase Decrease
Li+ day 7 vs. Ctrl 4 1 3
Li+ day 28 vs. Ctrl 9 4 5
Ctrl day 28 vs. 7 22 7 15
Li+ day 28 vs. 7 34 12 22
P,0.05, no specific FC limit. For complete lists, refer to tables S9–S12.
doi:10.1371/journal.pone.0102597.t007
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more powerful process of inherent bone healing, growth and
remodeling. The bone regeneration presumably also involves a
much larger subset of genes than the different implant groups
affect themselves. Moreover, the microarrays generate information
about several thousands of genes in a single experiment and it is
inevitable that genes with low FC disappear within this context.
Nevertheless, we cannot rule out the possibility that gene
expression differences demonstrating low FC in fact lead to a
significant biological outcome when related to sets of the same
genes and participate in the same biological process, as demon-
strated in earlier work[39]. When using the specific search criteria
(FC$1.5 or #21.5; p,0.05), a larger number of genes were
downregulated rather than upregulated over time. The result
demonstrates that the process of bone healing is powerful in the
early phases and decreases over time. The result was expected and
is in accordance with the results presented by others[29,30],
demonstrating that the early phases of osseointegration (days 4–14)
involve a large change in the expression of genes related to
proliferation, while immuno/inflammatory responses were most
prevalent at day 4 and skeletogenesis-associated genes dominated
in the later phase. In contrast to the above, Kojima et al.
demonstrated that more genes were upregulated during the later
time point of healing[32]. When considering the functional
clustering with respect to biological functions as a whole, no
major overall differences between Li+-containing samples and
Ctrls were revealed. Both implant groups demonstrated clusters
relating to the extracellular matrix organization, inflammatory
response, cell migration, blood vessel development and wound
healing. These were significantly downregulated over time, as
expected. Furthermore, both implant groups showed clusters
related to neuron development, differentiation axongenesis and
axon guidance. Interestingly, these clusters contained a larger
number of genes (Li+ 36; Ctrl 25) than skeletogenesis-related genes
(Li+ 8; Ctrl 12), a surprising finding. Similar results were recently
published by Ivanovski et al.[30], who demonstrated an over-
expression of neurogenesis-associated genes at day 14. These
findings indicate the formation of neurogenic tissue during the
osseointegration process. Apart from the regeneration of nerve
fibers, the role of the neurogenesis-associated genes during
osseointegration is not fully understood. However, few studies
Table 8. Validation of the microarray data by qPCR.
Gene
symbol Gene description
Affymetrix FC Ctrl
day 28 vs. 7 (n=6)
qPCR FC Ctrl day 28 vs. 7
(n=8)
Affymetrix FC Li+
day 28 vs. 7 (n=6)
qPCR FC Li+
day 28 vs. 7 (n =8)
Prss34 Protease, serine, 34 3.42* 15.97** 3.45* 22.75**
Prkca Protein kinase C, alpha 1.41*** 5.78* 1.29** 3.00***
Lrp5 Low density lipoprotein receptor-
related protein 5
- 21.26* 1.33
Fosl1 Fos-like antigen 1 21.26*** 1.26 21.30** 22.26**
Fzd2 Frizzled family receptor 2 21.68** 23.40** 21.66** 22.47***
Dkk1 Dickkopf 1 homolog (Xenopus
laevis)
- 21.91* 21.18
Sfrp5 Secreted frizzled-related protein 5 22.08** 21.01 -
Acan Aggrecan 22.77** 22.49* 22.31** 21.48
Aspn Asporin 22.91* 210.42*** 23.38** 22.19*
A2m Alpha-2-macroglobulin 23.19*** 26.19*** 24.01*** 25.79***
Cxcl2 Chemokine (C-X-C motif) ligand 2 24.76* 27.67* -
Relative gene expression fold change (FC) quantified by qPCR in Li+ or Ctrl peri-implant bone, 28 day vs. 7, postoperatively compared with Affymetrix FC (- =
undetectable expression). Unpaired Student’s t-test or Mann-Whitney test was used for statistical significance analyses (* p,0.05, ** p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0102597.t008
Figure 4. Gene expression analysis of FOSL1 and ASPN in peri-
implant bone. Relative gene expression level quantified by qPCR in
the peri-implant bone at 7 and 28 days postoperatively for Li+ and Ctrl
implants. A. FOSL1 and B. ASPN. Expressed as relative quantities
normalized to Ctrl at day 7 post-surgery (reference value 1). A paired
Student’s t-test or Wilcoxon signed-rank test was used for the Li+ vs. Ctrl
statistical analysis, whereas unpaired Student’s t-test or Mann-Whitney
test was used for statistical significance analysis of Li+ and Ctrl over time
(* p,0.05, ** p,0.01, ***p,0.001).
doi:10.1371/journal.pone.0102597.g004
Activated Wnt Signaling Pathway around Li+-PLGA Implants
PLOS ONE | www.plosone.org 9 July 2014 | Volume 9 | Issue 7 | e102597
have examined a regulatory connection between the central
nervous system and bone remodeling and it is known that leptin
regulates bone formation via the central nervous system[40,41].
However, this requires far more investigation. Further, the Ctrl
specimens demonstrated clusters related to the skeletal system,
bone development and ossification. The Li+-containing implants
also demonstrated clusters related to the skeletal system, but in
contrast to the Ctrl, also cartilage development and condensation.
Although not supported by the present histological observations,
this finding might suggest a more endochondral-like peri-implant
healing around Li+2containing implants and diverges from the
principal route of intramembranous bone regeneration. Only 1
annotation cluster, related to the regulation of cell activation, was
significantly upregulated over time for the Ctrl group, whereas 2
annotation clusters (related to hemostasis, wounding, regulation of
body fluids and cell activation) were significantly upregulated by
the Li+ group.
Figure 5. Immunostaning of b-catenin, FOSL1 and ASPN in decalcified bone- implant sections, 7 and 28 days postoperatively. A. Li+-
implant section at 7 days, strong b-catenin immunoreactivity in periosteum, endosteum and within bone marrow cavities in old cortical bone (arrows)
was observed. B. Li+-implant section at 7 days, b-catenin-positive bone-lining cells (black arrows) within bone marrow cavities. Mono- and
multinucleated b-catenin-positive cells facing the implant interface were observed, but also less positive multinucleated cells were observed (white
arrows). C. A similar distribution of b-catenin immunoreactivity was observed 28 days post-surgery in a Ctrl-implant section, with cells migrating into
PLGA remnants (black arrows). Occasionally, multinucleated cells with less intense b-catenin staining were found at the bone-implant interface (white
arrows). D. Li+-implant section at 7 days, FOSL1-immunostaining in periosteum, bone depressions and within bone marrow cavities in old cortical
bone (arrows). E. FOSL1-positive bone-lining cells within bone marrow cavities at 7 days in a Li+-implant section (black arrows). Mono- and
multinucleated cells positive for FOSL1 migrated into, or were seen in close vicinity of PLGA remnants (black arrows). Some multinucleated cells less
positive for FOSL1 were occasionally observed facing the bone-implant interface (white arrows). F. Ctrl-implant at 28 days, both mono- and
multinucleated FOSL1-positive cells were detected at the bone-implant interface (black arrows). G. Li+-implant section at 7 days, ASPN
immunoreactivity in periosteum, bone depressions and bone marrow cavities (arrows) of the cortical bone. H. Li+-implant section at 7 days, ASPN-
positive osteoblast seams within bone marrow cavities and mesenchymal-like and multinucleated cells located at the PLGA-bone interface (black
arrows). Occasional multinucleated cells that displayed lower immunoreactivity were observed at the interface (white arrows). I. A similar distribution
of ASPN immunoreactivity was detected 28 days post-implantation in a Ctrl-implant section, showing ASPN-positive cells actively migrating into the
polymeric remnants (black arrows). All sections (A-I) were counterstained with hematoxylin, control sections with isotype staining were used (data
not shown). B = bone; P = denotes the location of the (removed) PLGA implant, * = indicates the PLGA remnants, BM = bone marrow. No
qualitative or quantitative histological differences were detected between Li+ and Ctrl.
doi:10.1371/journal.pone.0102597.g005
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The KEGG pathway analysis revealed 6 pathways that were
significantly downregulated over time (day 28 vs. 7) for the Ctrl
implants. They included focal adhesion, ECM-receptor interac-
tion, arginin and proline metabolisms and axon guidance. In
another study, these pathways were upregulated during the early
phase of intramembranous bone regeneration[29], which is in line
with our findings. Nine pathways were significantly downregulated
over time for the Li+ group. In addition to focal adhesion, ECM-
receptor interaction, arginin and proline metabolism and axon
guidance, pathways related to cancer, involving the Wnt signaling
pathway, were also downregulated over time. For the Ctrl group,
no pathways were significantly upregulated over time, while the
Li+ group showed 2 pathways as significantly increased at day 28.
This included the hematopoetic cell lineage, which Wise et al.[29]
claimed was downregulated in the early bone healing phase, and is
in line with our result. Due to the above-mentioned pathway
analysis indicating that the Wnt signaling pathway was affected
over time by Li+, specific Wnt-related genes were searched for in
the KEGG database. This revealed an increased number of
affected Wnt-related genes in the context of Li+. Furthermore,
according to the KEGG database, 98 genes are associated with the
Wnt signaling pathway and our results suggest that 4–9% of the
Wnt signaling genes were specifically regulated by Li+ (at each
time point), while approximately 34% was regulated in the Li+
group and 22% in the Ctrl group over time. This is regarded as a
considerable proportion of affected genes within the same
biological process. The Wnt-specific genes showed an overall
low FC. However and as discussed above, the Wnt cascade is a
well-conserved, essential pathway in osteogenesis and it is
recognized that even subtle changes in amplitude and the duration
of numerous Wnt-related markers might regulate the entire
pathway[9]. Moreover, a low FC may therefore result in a
significant biological outcome and this is regarded as a valuable
data outcome from the present study. Taken together, this also
illustrates the importance of small alterations in gene expression.
Both activators and inhibitors of the Wnt pathway were
significantly affected over time. b-catenin is a well-documented
key mediator of the Wnt signaling pathway[42,43] and, interest-
ingly, the b-catenin interaction protein, a negative regulator of the
Wnt signaling pathway[44], was downregulated for Li+ compared
with Ctrl, 7 days post-surgery. Further, in our study, b-catenin was
downregulated over time by Li+, but it was not affected in the Ctrl
group, indicating an increased activity in the Wnt signaling
pathway by Li+ during the early stages of osseointegration and
reduced activity in later stages. Our result is also in line with earlier
studies demonstrating enhanced Wnt signaling during the early
phase of bone regeneration[29,30]. Other signs of an affected Wnt
signaling pathway in bone around Li+ implants was demonstrated
by the significant increase in the gene expression of FOSL1 at 7
days post-implantation, compared with Ctrl. FOSL1, also called
FRA-1, which is part of the transcription factor, activator protein-
1 (AP-1), is a downstream target gene of canonical Wnt
signaling[45], thus demonstrating an active signaling pathway
around Li+ containing specimens. FRA-1 positively regulates the
bone-forming activity of osteoblasts and is active during osteoclast
differentiation. It has been suggested that ectopic expression
induces bone formation and osteosclerosis[46,47]. Heo et al.
reported an increase in FRA-1 gene expression in cells stimulated
with Li+[48], a result supported by our data. Moreover, we have
previously demonstrated a significant increase in this gene
expression in osteoarthritic (OA) cartilage[49]. This is important,
as an increase in subchondral plate thickness is a characteristic of
OA pathogenesis and underlines the essential function performed
by FOSL1 in bone regeneration.
Li+-containing implants displayed at 28 days post-surgery a
significant upregulation in ASPN gene expression compared with
Ctrls. ASPN is a member of the small leucine-rich repeat
proteoglycan (SLRP) family (subgroup of the leucine-rich repeat
(LRR) superfamily of extracellular matrix proteins) and is
recognized as a negative regulator of both early- and late-stage
chondrogenesis, with increased expression in OA, and is expressed
in periosteum during development[50]. Kalamajski et al. have
shown that ASPN binds calcium and collagen type 1 and is
suggested to be involved in osteoblast-driven biomineralization.
An increase in the gene expression of Osteorix and RUNX2 was
also reported in relation to ASPN[51]. It has also been suggested
that the active canonical Wnt pathway inhibits chondrogenesis
and is implicated in the pathogenesis of OA[52,53]. Moreover, a
recent publication reported that sclerostin, an extracellular
inhibitor of the canonical Wnt pathway that is primary expressed
by osteocytes and binds to LRP5/6[54,55], interacts with
ASPN[56]. We speculate that the significant increase in ASPN
gene expression around Li+ implants at 28 days post-implantation
is somehow related to an active Wnt signaling caused by the locally
released Li+, or suggests a connection between Wnt signaling and
ASPN expression. The distribution of b-catenin, FOSL1 and
ASPN in bone was investigated using IHC. Unfortunately, some of
the sections were of inferior sample quality due to artifacts created
during sample preparation and it was therefore not possible to
perform meaningful comparisons at the actual interface between
Figure 6. Total bone area around PLGA implants. Histomor-
phometry. A. Total bone area (BA) (%) after 7 and 28 days. The diagram
shows mean values and standard deviations. An independent samples
T-test was used to compare day 28 vs. 7 for Li+ and Ctrl respectively
(n = 6–7, * p,0.05, ** p,0.01, ***p,0.001). B. Examination areas (A and
B) of histological samples.
doi:10.1371/journal.pone.0102597.g006
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PLGA and bone. However, positive stainings for these markers
were shown in periosteum and bone marrow cavities. Immuno-
reactivity for b-catenin, FOSL and ASPN was also observed in
cells actively migrating into the polymeric remnants, thus
demonstrating that the expressions of these markers were located
within tissues with osteoblast progenitor cells and in areas with
active woven bone formation. Moreover, multinucleated cells at
the bone-implant interface were occasionally negatively stained for
these markers. However, in order fully to investigate potential
differences in protein expression in the vicinity of the implants,
additional techniques for quantitative analyses will be needed (e.g.
proteomics or western blot) and the precise role of these genes in
the modulation of peri-implant healing requires further examina-
tion. In addition to the distribution and expression of b-catenin,
FOSL1 and ASPN, the histomorphometric analysis demonstrated
a significant decrease in bone area for both implant types over
time. This may be a result of the mild inflammatory response that
could be induced by small PLGA particles (de-attached during the
implantation process) and/or degradation products over
time[57,58], although further evaluation is needed. Activated
macrophages and a foreign-body reaction towards biomaterials is
known to secrete a wide range of cytokines[59] that are regarded
as osteoclastogenic[60], thereby possibly affecting bone resorption
in the vicinity of implants. Further, both osteoblastic activity and
the number of macrophages and giant cells have been studied in
the context of PLGA[23]. These results were supported by the
present histological evaluation showing the occasional presence of
multinucleated giant cells within the space between bone and
PLGA remnants. In order to further investigate the spatial
localization of different cell types in the close vicinity of the
polymeric implants, the expression of periostin, involved in the
early stages of osteoblast differentiation[61], and the calcitonin
receptor, expressed on osteoclasts[62], were visualized by IHC.
Positive stainings were observed at both time points for both
markers, although no qualitative or quantitative evaluation over
time was possible (due to inferior sample quality). Periostin-positive
cells were distributed throughout the regenerated tissue and
multinucleated cells positive for the calcitonin receptor were
observed at the bone-implant interface. Occasionally, periostin-
and calcitonin receptor-negative multinucleated giant cells were
observed in the close vicinity of the polymer implants. The absence
of these and the abovementioned markers, as well as the
localization of these cells, likely indicate foreign-body-reaction-
associated giant cells and/or alternatively inflammation-associated
Figure 7. Spatial localization of periostin and calcitonin receptor in decalcified bone-Ctrl implant sections, 7 and 28 days
postoperatively. Staining with antibodies against periostin and calcitonin receptors in decalcified paraffin-embedded sections of the bone-implant
interface after 7 or 28 days of implantation to rat tibia. A. Ctrl-implant section after 7 days, immunoreactivity for periostin was observed over the
periosteum and within bone marrow cavities of old cortical bone (arrows). B. Periostin-positive cells were distributed throughout the regenerated
tissue in Ctrl-implant section 7 days postoperatively. Osteoblast bone lining cells (some indicated by black arrows) were stained strongly for periostin.
Immunoreactivity for periostin was observed in mono- and multinucleated cells situated in the close vicinity of the PLGA implant, but occasional less
stained multinucleated cells were also observed (white arrows). C. A similar distribution of immunohistochemical reaction for periostin was detected
after 28 days in a Ctrl-implant section, with cells migrating into the polymeric remnants (arrows). D. 7 days postoperatively Ctrl-implant section,
immunohistochemical reaction for calcitonin receptor over the inner osteogenic layer of periosteum. E. 7 days after implantation Ctrl-implant section,
positive staining for the calcitonin receptor was detected on both mono- and multinucleated cells localized preferentially at osteoblast seams and at
the bone-implant interface. Osteoclasts and mononuclear precursors stained for the calcitonin receptor are indicated (black arrows). Occasional
multinucleated cells negative for calcitonin-receptor immunoreactivity were observed facing the bone-implant interface (white arrows). F. A similar
distribution of immunohistochemical reaction for calcitonin receptor was detected after 28 days in a Ctrl-implant section, with cells migrating into the
polymeric remnants (black arrows). Some multinucleated cells negative for calcitonin receptor are shown (white arrows). All sections (A-F) were
counterstained with hematoxylin, control sections with isotype staining was used (data not shown). B = bone; P = denotes the location of the
(removed) PLGA implant, * = indicates the PLGA remnants, BM = bone marrow. No qualitative or quantitative histological differences were detected
between Li+ and Ctrl.
doi:10.1371/journal.pone.0102597.g007
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cells. Some of the most downregulated inflammation related genes
over time for both groups revealed in the microarray analysis were
A2M and CCL7, whereas CXCL2 was downregulated only in the
Ctrl group. A2M is a protease inhibitor known to exert a key role
in the immune system although its mechanisms are not completely
understood. It is associated with tissue destruction in periodontitis
and is suggested to inhibit inflammation and to suppress
proliferation of microorganisms[63]. A2M is also implicated in
cartilage degradation, it is known to interact with the osteogenic
growth peptide, osteoprotegerin (OPG), and suggested to inhibit
BMP-1[64]. Analysis of proteins bound to different biomaterial
surfaces recently identified A2M resorbed on PLGA [65]. Earlier
studies with biomaterials with this pre-adsorbed protein facilitate
macrophage fusion and formation of foreign body giant cells[66].
The progression of inflammation and foreign body response
involves the migration of monocytes and macrophages to the site
of implantation, which is guided by chemokines and other
chemoattractants. The CCL7 gene encodes the monocyte
chemotactic protein 3 (MCP-3), a chemokine implicated as a
key mediator of pro-inflammatory pathways, recognized to
activate leukocytes and to attract monocytes/macrophages during
inflammation[59]. CCL7 has further been identified as a MSC
homing factor in cardiac tissue[67], a function of the chemokine
that Shinohara et al. also recently have suggested to participate in
bone repair[68]. CXCL2 (also known as MIP-2) is involved in
recruitment of monocytes and macrophages into inflamed tissues
by bone marrow MSCs[69], and both mast cells and macrophages
are known to secrete this chemokine that also acts as a neutrophil
chemoattractant during tissue inflammation[70]. Chemokines are
believed to play important functions in several aspects of bone
metabolism including for instance recruitment of leukocytes and
osteoclast maturation, and recently CXCL2 was observed to be
upregulated at fracture sites of diabetic mice[71]. However,
despite that the functional cluster analysis demonstrated a slight
change in enrichment score between Li+ and Ctrl implants with
respect to the inflammatory response and the above-mentioned
genes, no qualitative histological differences were detected and
further evaluation is required.
Taken together, our results demonstrated a large number of
genes as regulated over time, and with a large subset of Wnt-
related markers involved. Although the significantly increased
expression of the Wnt-associated genes, FOSL1 and ASPN, was
related to Li+, no obvious effect of an activated Wnt pathway in
the context of increased bone regeneration was observed. We want
to stress here that this observation was made for a bioresorbable
material, PLGA with and without added Li+, and may be different
for different biomaterials. On the other hand and very interest-
ingly, both implant groups showed a significant decrease in bone
area over time. This might reflect a sustained mild inflammatory
response caused by PLGA degradation products. Our data
provide a basis for further studies of the function of Wnt-related
genes in peri-implant healing around polymeric implants and the
modulatory effect of Li+, although further progress will be required
to optimize Li+ administration for a local therapeutic effect.
Conclusions
In the present study, Li+ was successfully released from PLGA
implants out to surrounding bone in a sustained release fashion
and the gene expression profile during peri-implant healing in a
rat tibia model was investigated. Microarray analysis revealed a
large number of significantly differentially regulated genes within
the 2 implant groups (PLGA with/without Li+) over time. The
annotation cluster analysis demonstrated, for both implant groups,
skeletal system morphogenesis/development and, surprisingly, the
Li+-containing implants were also related to cartilage development
and condensation as well as to the Wnt signaling pathway. Li+
appears not to be a strong inducer of early bone growth around
PLGA implants although the qPCR analysis demonstrated that
Li+ activated the Wnt signaling pathway at 7 days post-surgery, as
demonstrated by a significant increase in FOSL1 expression. A
possible impact on the Wnt signaling pathway via ASPN
expression was observed at 28 days post-surgery. The decrease
in bone area that was observed around both implant groups may
to some extent be explained by the presence of multinucleated
cells, possibly caused by the polymeric degradation products. The
collected data indicate that Li+ is a mild bone growth modulator in
the context of bone-anchored implants and the Wnt signaling
pathway when administered locally in the present dose and during
the time frame of the study, up to 28 days.
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